Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmacy Times
NOVEMBER 4, 2023
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmacy Times
NOVEMBER 4, 2023
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmacy Times
NOVEMBER 4, 2023
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 4, 2023
Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmacy Times
NOVEMBER 4, 2023
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Expert insights. Personalized for you.
52 
Let's personalize your content